Stock listing

Frankfurt:W33 BioVersys AG Aktie

German listing (Frankfurt) of BioVersys AG · home listing SIX Swiss:BIOV

Follow BioVersys AG into a list and get an email when it puts out news.

Share price · FWB:W33

€24.40 EUR -0.20 (-0.8%)

Close on Nov 20, 2026

This year +5.5% · daily closes, Dec 1, 2025 – Nov 13, 2026, adjusted for splits
Day range
€24.40 – €25.00 EURNov 20, 2026
Market cap
€142.9M EURAt the close on Nov 20, 2026 · price × 5.85M shares outstanding
Traded on an average day
€756 EURMedian day 0 shares · 47 days with no trades · last 3 months, Aug 20, 2026 – Nov 13, 2026
BioVersys AG logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
SIX Swiss:BIOV · Home22.10 CHF-1.80 (-7.5%)9,07823.5023.9022.1023.90Close on Nov 20, 2026
Frankfurt:W33€24.40 EUR-0.20 (-0.8%)—€24.60€25.00€24.40€24.60Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 13, 2026 · FWB:W33 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€24.50+0.739+3.1%€23.99€24.63€23.900
€23.76-0.682-2.8%€24.15€24.22€23.730
€24.44+0.269+1.1%€24.60€24.68€24.409
€24.17+0.287+1.2%€24.17€24.23€23.989
€23.89-0.14-0.6%€24.11€24.23€23.699
€24.03+0.09+0.4%€24.03€24.03€24.0320
€23.94-0.219-0.9%€24.11€24.23€23.840
€24.15-0.023-0.1%€24.15€24.47€24.06140
€24.18-0.453-1.8%€24.64€25.18€24.160
€24.63-0.659-2.6%€25.43€25.51€24.290
€25.29+0.117+0.5%€25.20€25.39€25.150
€25.17+0.044+0.2%€24.94€25.35€24.750
€25.13-0.075-0.3%€25.13€25.93€24.780
€25.20-0.602-2.3%€25.25€25.32€25.180
€25.81+0.152+0.6%€25.20€26.01€25.100
€25.65-0.133-0.5%€25.45€25.86€25.250
€25.79-0.458-1.7%€25.80€25.86€25.770
€26.24+0.164+0.6%€26.20€26.32€26.040
€26.08-0.143-0.5%€26.08€26.08€26.080
€26.22-0.196-0.7%€26.22€26.45€26.2210
€26.42-0.411-1.5%€26.42€26.42€26.420
€26.83+0.268+1.0%€26.64€26.87€26.610
€26.56+0.314+1.2%€26.20€26.57€25.980
€26.25-0.384-1.4%€26.37€26.40€26.090
€26.63-0.211-0.8%€26.63€26.63€26.630
€26.84+0.247+0.9%€26.84€26.84€26.84100
€26.60-0.416-1.5%€26.60€26.60€26.60100
€27.01-0.084-0.3%€26.94€27.21€26.830
€27.10-0.311-1.1%€26.93€27.13€26.760
€27.41+0.262+1.0%€27.23€27.47€27.150
€27.15+0.654+2.5%€27.28€29.84€26.9817
€26.49-0.221-0.8%€26.49€26.49€26.490
€26.71-1.137-4.1%€26.47€26.73€26.400
€27.85+1.486+5.6%€26.38€28.08€26.05100
€26.36-0.825-3.0%€25.90€26.48€25.900
€27.19+1.07+4.1%€27.26€27.33€27.190
€26.12-1.549-5.6%€26.23€26.25€25.920
€27.67-0.042-0.2%€27.87€27.94€27.340
€27.71-0.553-2.0%€27.71€27.73€27.600
€28.26+0.375+1.3%€28.46€28.62€28.160
€27.89-0.266-0.9%€27.89€27.89€27.880
€28.15+0.60+2.2%€27.36€28.23€27.35170
€27.55-1.429-4.9%€27.62€27.62€27.440
€28.98+1.541+5.6%€28.98€28.98€28.980
€27.44-0.123-0.4%€27.74€27.74€27.430
€27.56-0.303-1.1%€27.38€27.94€27.330
€27.87-0.465-1.6%€28.07€28.10€27.790
€28.33-0.878-3.0%€28.40€28.40€28.250
€29.21-0.293-1.0%€29.21€29.39€28.920
€29.50+1.086+3.8%€29.19€29.80€29.020
€28.42-0.462-1.6%€28.42€28.48€28.150
€28.88-0.152-0.5%€28.90€28.98€28.41846
€29.03+3.374+13.2%€27.92€29.41€27.7750
€25.66+0.089+0.3%€26.38€26.50€25.505
€25.57-0.99-3.7%€26.35€26.43€25.420
€26.56+1.095+4.3%€25.61€26.63€25.580
€25.46-0.516-2.0%€26.29€26.39€25.150
€25.98-0.242-0.9%€25.98€25.98€25.980
€26.22+0.295+1.1%€25.79€26.23€25.770
€25.93-0.128-0.5%€25.93€25.93€25.930
€26.05-0.81-3.0%€26.05€26.05€26.050
€26.86-0.115-0.4%€26.48€27.96€26.29100
Ticker
Frankfurt:W33
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All BioVersys AG news

BioVersys AG on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 24 in all · newest Sep 9, 2026 · oldest 2025
Decks
3 decks · latest Sep 9, 2026

Where BioVersys AG is listed

ListingExchangeCountryCurrency
SIX Swiss:BIOV · Home listingSIX SwissSwitzerlandCHF
Frankfurt:W33 · This pageFrankfurtGermanyEUR
Turquoise:BIOVZTurquoiseUnited KingdomCHF

Valuation

EV/sales 102× against a median of 45.5×: 7th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
81.82M CHF
P/E
Loss
EV/sales
102×
EV/EBITDA
Negative EBITDA
Price/book
2.9×
Gross margin
−386.6%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.5×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BioVersys AG · SIX:BIOVUS$154.1MUS$97.45Mn/a102×n/a2.9×n/a0.5×n/a
TaiGen Biopharmaceuticals Holdings Limited · TPEX:4157US$161.1MUS$133.4M34.2×17.1×46.8×5.2×60.5%0.0×n/a
ImmuneOncia Therapeutics Inc. · KRX:424870US$160.0MUS$90.35Mn/an/an/a2.1×n/a0.0×n/a
Baijin Life Science Holdings Limited · HKEX:1466US$160.0MUS$158.1Mn/a13.9×n/a6.8×−42.4%0.1×n/a
Jiangsu Recbio Technology Co., Ltd. Class H · HKEX:2179US$157.3MUS$230.0Mn/a124×n/a2.1×n/a1.4×n/a
InflaRx N.V. · NASDAQ:IFRXUS$153.3MUS$135.7Mn/a4,215×n/a19.5×n/a0.0×1.61
Polaris Group · TWSE:6550US$153.0MUS$154.8Mn/a75.1×n/a1.1×n/a0.5×n/a
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541US$152.0MUS$64.59Mn/a2.9×n/a1.6×−141.7%0.6×n/a
Saniona AB · OMXSTO:SANIONUS$151.6MUS$104.0M8.4×2.5×5.2×2.8×43.2%0.0×n/a
Palisade Bio, Inc. · NASDAQ:PALIUS$150.6MUS$36.96Mn/a73.9×n/a1.3×n/a0.0×1.41
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
Median of the othersUS$153.1MUS$118.7M21.3×45.5×26.0×2.5×0.4%0.0×1.61

Forecasts

Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
65.80 CHF · Analysts' mean
EPS, year to Dec 2026
-5.81 · 6 analysts
Revenue, year to Dec 2026
3.22M · 5 analysts

Team and board

Officers

OfficerRole
Marc GitzingerChief Executive Officer & Founder
Hernan LevettChief Financial Officer
Anca CighiHead of Investor Relations and Communications
Alexander LedererHead of Intellectual Property
Daniel RitzChief Scientific Officer
Fiona GaoHead of Legal
Glenn DaleChief Development Officer
Jonathan James ButcherHead of Business Development & Alliance Management

Board

DirectorRole
Seng Chin MahChairman
David HunstadBoard Member
Marc GitzingerChief Executive Officer & Founder
Marina von SchönauBoard Member
Simona SkerjanecBoard Member
Ulrik SchulzeBoard Member

Events

QuarterResultsShare move
Quarter to Mar 31, 2026Apr 1, 2026+3.5%
Quarter to Sep 30, 2025Dec 3, 2025+7.7%
Q2 2025Sep 10, 2025−3.8%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings46 slidesSep 9, 2026
H1 2026 Earnings PresentationEarnings21 slidesSep 9, 2026
FY2025 Earnings PresentationEarnings27 slidesMar 18, 2026

Open Decks

Financials

Annual, in CHF

Income statement

LineFY2025FY2024
Revenue800.0K0
Cost of revenue3.89M3.95M
Gross profit-3.09M-3.95M
Research and development16.5M12.9M
Operating income-20.0M-18.7M
Depreciation and amortization297.0K282.0K
EBITDA-19.7M-18.4M
Interest expense1.08M1.04M
Income before tax-21.8M-18.7M
Net income-21.8M-18.7M
Earnings per share, basic-3.73-3.16

Balance sheet

LineFY2025FY2024
Cash and equivalents82.5M26.6M
Short-term investments6.00M
Current assets89.9M34.4M
Total assets90.6M35.0M
Accounts payable2.47M706.0K
Current liabilities8.90M9.67M
Long-term debt21.3M13.6M
Total liabilities30.8M24.3M
Shareholders' equity59.8M10.7M
Shares outstanding5.85M5.91M

Cash flow

LineFY2025FY2024
Cash from operations-21.9M-15.6M
Capital spending-216.0K-38.0K
Free cash flow-22.2M-15.6M
Change in cash56.4M1.58M

Open Financials

Cap table

Built by 6ix from BioVersys AG’s releases

Common shares
5,854,584
Fully diluted
5,854,584

Fully diluted

LineShares
Common shares5,854,584

Share count over time

CountShares
Nov 22, 20265,854,584

Open Cap table

Shareholders

Register

HolderSharesOf the companyAs of
AMR Action Fund GP, LLC923K16.0%Feb 7, 2025
UBS Fund Management (Switzerland) AG331K5.7%Sep 19, 2025
Glaxo Group Limited253K4.4%Aug 6, 2025
ViaValor AG200K3.4%Nov 14, 2025
Marc Jaquet183K3.1%Aug 6, 2025
Barrus AGNov 14, 2025
CandriamFeb 11, 2025
BioVersys AGMar 19, 2025
n/a n/aFeb 2, 2026

Big stakes

StakeStakeSharesDateFiling
AMR Action Fund GP, LLC15.98%923KFeb 7, 2025SIX significant shareholder notification
UBS Fund Management (Switzerland) AG5.69%331KSep 19, 2025SIX significant shareholder notification
Glaxo Group Limited4.35%253KAug 6, 2025SIX significant shareholder notification
Candriam3.91%Feb 11, 2025SIX significant shareholder notification
ViaValor AG3.43%200KNov 14, 2025SIX significant shareholder notification
Marc Jaquet3.14%183KAug 6, 2025SIX significant shareholder notification

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Alexander LedererHead of Intellectual Property · Since at least Nov 5, 2026
Anca CighiHead of Investor Relations and Communications · Since at least Apr 2, 2026
Daniel RitzChief Scientific Officer · Since at least Mar 31, 2026
David HunstadBoard Member · Since at least Apr 30, 2026
Fiona GaoHead of Legal · Since at least Nov 5, 2026
Glenn DaleChief Development Officer · Since at least Apr 22, 2026
Hernan LevettChief Financial Officer · Since at least Sep 9, 2026
Jonathan James ButcherHead of Business Development & Alliance Management · Since at least Nov 4, 2026
Marc GitzingerChief Executive Officer & Founder · Since at least Sep 9, 2026
Marina von SchönauBoard Member · Since at least Apr 30, 2026
All 13 people
PersonSeat
Seng Chin MahChairman · Since at least Apr 30, 2026
Simona SkerjanecBoard Member · Since at least Apr 30, 2026
Ulrik SchulzeBoard Member · Since at least Apr 30, 2026

Open People

Log in to ask 6ix AI your own questions about BioVersys AG.